On November 19, Veracyte rose 5.67% in Regular Trading, trading at $25.54/share, with turnover of $14.98 million.
The latest publicly available catalyst is a rebound following the company’s recent post-earnings volatility: Veracyte previously reported third-quarter adjusted EPS of $0.51 and revenue of $151.8 million, both above consensus, but narrowed full-year revenue guidance to $590 million-$593 million from $590 million-$596 million, which had triggered a sharp selloff.
Subsequently, several brokers cut their price targets to $35, including Leerink, UBS and Guggenheim, while maintaining a more cautious stance on the shares. The current rise appears to reflect stabilization after that reset in expectations rather than a new fundamental announcement on the day.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments